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A series of 2-(p-substituted phenyl)-5-[(4-substituted phenyl) sulfonylamido]-benzoxazoles were synthe-
sized and tested for their antimicrobial activities. The structures of the new derivatives were elucidated 
by spectral techniques. The minimum inhibitory concentrations (MIC) of the new benzoxazoles were 
determined against standard bacterial and fungal strains and drug-resistant isolates and compared to those 
of several reference drugs.
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INTRODUCTION
The treatment of infectious diseases still remains to be an important and challenging 
problem due to emerging infectious diseases and increasing number of multi-drug 
resistant microbial pathogens [3, 13]. In spite of the large number antibiotics and 
chemotherapeutics, the emergence of old and new antibiotic resistant bacterial strains 
constitutes a substantial need for the new class of potent antimicrobial agents [4, 11]. 
Heterocyclic compounds play an important role in designing a new class of struc-
tural entities of medicinal importance with new mechanisms of action. Benzoxazoles, 
structural isosteres of natural nucleotides that can interact with biopolymers, consti-
tute an important class of heterocyclic compounds with antimicrobial and antifungal 
activity [1–2, 9, 12, 14–17]. 
A benzoxazole derivative; calcimycin is a carboxylic polyether antibiotic from a 
strain of Streptomyces chartreusis (NRRL 3882). It was found to be very active 
against Gram-positive bacteria including some Bacillus, Micrococcus strains [12]. 
Routiennocin, 3-hydroxy-11,15-desmethyl analog of calcimycin and cezomycin, 
3-demethylamino analog of calcimycin are found to be highly active against Bacillus 
cereus, B. negaterium, Micrococcus luteus and Streptomyces rimosus [14]. Additionaly 
frankamide; 11-demethyl cezomycin is another calcimycin analogue which has activ-
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ity against B. subtilis, Staphylococcus aureus, Enterococcus faecalis and against 
several plant pathogenic fungal strains [9].
In the last years we described the synthesis of different derivatives of some 
2,5-di substituted benzoxazoles and the results of assays on their in vitro antimicro-
bial activity against some Gram-positive, Gram-negative bacteria and fungus 
Candida albicans [1–2, 15–17]. In the present study, we report a new series of 
2-(p-sub stituted phenyl)-5-[(4-substituted phenyl) sulfonylamido]-benzoxazoles. 
2–19 has been synthesized using a two-step procedure. Several control drugs and new 
synthesized benzoxazole compounds were evaluated for their antibacterial and anti-
fungal activity against standard strains and their drug-resistant isolates.
MATERIALS AND METHODS
Chemistry
Chemicals and solvents were purchased from Sigma-Aldrich (Munich, Germany) and 
Fisher Scientific (Pittsburgh, PA, USA), and used without further purification. Silica 
gel HF254 chromatoplates (0.3 mm) were used for thin layer chromatography, and 
chloroform was employed as mobile phase. Melting points were recorded on a Stuart 
Scientific SMP 1 instrument (Bibby Scientific Limited, Stone, Staffordshire, UK) and 
are uncorrected. NMR spectra were recorded on a Varian Mercury 400 MHz NMR 
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spectrometer (Palo Alto, CA, USA) in CDCl3; tetramethylsilane (TMS) was used as 
an internal standard. The mass spectra were recorded on a Waters ZQ Micromass 
LC-MS spectrometer (Milford, MA, USA) using the ESI(+) method. Elemental 
analyses were performed on an LECO 932 CHNS instrument (St. Joseph, MI, USA), 
and results were within ± 0.4% of theoretical values. For the synthesis of compounds 
(2–19) firstly, 5-amino-2-(p-substituted phenyl)-benzoxazoles (1a–c) were synthe-
sized by heating 2,4-diaminophenol with p-substituted benzoic acid in polyphos-
phoric acid (PPA). Then compounds 2–19 were obtained by treating a solution of 
p-substituted-benzenesulfonyl chlorides with 5-amino-2-(p-substituted phenyl)-ben-
zoxazoles (1a–c) [1, 10]. All the compounds 2–19 were prepared as new products. 
The structures of new benzoxazole derivatives (Fig. 1) were confirmed by their 
1H/13C-NMR, Mass and elementary analysis (Table 1). 
Microbiological assay
Materials used in the microbiology study were Mueller Hinton Agar (MHA) (Merck, 
Darmstadt, Germany), Mueller Hinton Broth (MHB) (Merck), Sabouraud Dextrose 
Agar (SDA) (Merck), Sabouraud Liquid Medium (SLM) (Merck) and RPMI-1640 
medium with L-glutamine (Sigma) buffered pH 7 with 3-[N-morpholino]-
propansulfonic acid (MOPS) (Sigma) were used for microbial cultures. Standard 
powders of ampicillin (Mustafa Nevzat İlaç Sanayii), cefuroxime (Mustafa Nevzat 
İlaç Sanayii), ciprofloxacin (Fluka), imipenem (Fluka), meropenem (AstraZeneca), 
fluconazole (Sigma) and amphotericin B (Riedel de Haen, Seelze) were used as stand-
ard antimicrobial agents. Microorganisms used in the assay were; Escherichia coli 
ATCC 25922, Pseudomonas aeruginosa ATCC 27853, Staphylococcus aureus ATCC 
29213, Enterococcus faecalis ATCC 29212 and Candida albicans ATCC 10231 
standard strains and clinical isolates provided from Trakya University Health Center 
for Medical Research and Practice (Edirne, Turkey) were used in the study. 
For microbiological assays, stock solutions of the test compounds were prepared 
in DMSO. Antibiotic solutions were prepared according to the guideline of CLSI 
M100-S18. Antimicrobial susceptibility testing was performed through CLSI 
M100-S18 [5] and CLSI M27-A3 [6] directions. Bacterial isolates were subcultured 
in MHA plates and incubated over night at 37 °C and C. albicans was subcultured in 
SDA plates at 35 °C for 24–48 h. The microorganisms were passaged at least twice 
to ensure purity and viability. Pure colonies were transferred to MHB and SLM for 
bacteria and fungi, respectively. They were incubated in the appropriate conditions 
overnight. After incubation, the bacterial suspensions used for inoculation were pre-
pared at 105 CFU/mL by diluting fresh cultures at MacFarland 0.5 density (107 CFU/
mL). Yeast suspensions were also prepared according to McFarland 0.5 density and 
a working suspension was made by a 1 : 100 dilution followed by a 1 : 20 dilution of 
the stock suspension (2.5 × 103 CFU/mL). Susceptibility testing was performed with 
MHB for bacteria and RPMI-1640 medium with L-glutamine buffered pH 7 with 
MOPS for fungi. The solution of the newly synthesized compounds and standard 
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drugs were prepared at 1024, 512, 256, 128, 64, 32, 16, 8 µg/mL and 16, 8, 4, 2, 1, 
0.5, 0.25, 0.125 µg/mL concentrations, respectively, by diluting the stock concentra-
tions with a multichannel pipette. 
After dilution, a 10 µL bacterial or fungal inoculum was added to each well of the 
microdilution trays. The trays were incubated at 37 °C for bacteria and 35 °C for 
fungi, in a humid chamber and MIC endpoints were read after 24 h of incubation. The 
lowest concentration of the compound that completely inhibits macroscopic growth 
was determined and minimum inhibitory concentrations (MICs) were reported. All 
organisms were tested in triplicate in each run of the experiments. Solvents, pure 
microorganisms and pure media were used as control wells. 
RESULTS
The desired benzoxazole derivatives were synthesized using a two-step procedure. 
Firstly, 5-amino-2-(p-substituted phenyl)-benzoxazoles were synthesized by heating 
2,4-diaminophenol with p-substituted benzoic acid in polyphosphoric acid (PPA). 
Then compounds 2–19 were obtained by treating a solution of p-substituted-benzene-
sulfonyl chlorides with 5-amino-2-(p-substituted phenyl)-benzoxazoles as shown in 
Fig. 1.
Their structures were elucidated with Mass, 1 H NMR and 13C NMR spectroscopy. 
Their purity was analyzed through elemental analysis that was within ±0.4% of theo-
retical values. Physical and spectral data of the synthesized benzoxazole derivatives 
are given in Table 1. In the 1H NMR spectra of the compounds (2–19) of the signal 
of the NH proton was observed at 10.70–10.10 ppm as a singlet band, aromatic OCH3 
protons were observed at 3.74–3.80 as singlet band for compounds 4, 10. Aromatic 
CH3 protons appeared at 2.31–2.30 ppm as singlet band for compounds 3, 14, 16. 
Besides all the aromatic protons were observed at the expected regions. On the other 
hand, mass spectra of the compounds showed M+ +H, M+, M+ -H peaks, since the 
electrospray ionization method was employed, in accordance with their formulas. 
Additionally, 13C NMR spectra of compounds were evaluated.
All the newly synthesized benzoxazoles (2–19) and standard drugs were evaluated 
for their antimicrobial activity against some Gram-positive, Gram-negative bacteria 
and fungus C. albicans and their drug-resistant isolates. The results are presented in 
Table 2. 
DISCUSSION
In the last few years, we described the synthesis of some 2,5-disubstituted-benzoxa-
zoles and the results of assays on their in vitro antimicrobial activity against some 
Gram-positive, Gram-negative bacteria, along with the microfungus C. albicans and 
their isolates [1, 2, 15–17].
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In this study, our goal was to investigate the role of different (p-substituted-pheny)
sulfonylamido groups on the 5th position of 2-(p-substituted phenyl)benzoxazole ring 
as potential antimicrobial agents. According to Table 2, compounds 2–19 exhibited 
broad antibacterial activity with MIC values of 64–1024 µg/mL. 256–512 µg/mL 
against S. aureus and the MRSA isolate. All MRSA strains are known to be resistant 
to penicillins, cephalosporins, cephems and other beta-lactam antibiotics, regardless 
Table 2
In vitro antimicrobial activities of the newly synthesized benzoxazole derivatives in comparison with control 
drugs (MIC in µg/mL)
Comp. No. E.c. E.c.* P.a. P.a.* S.a. S.a.* E.f. E.f.* C.a. C.a.*
2 128 128 128 128 256 256 128 128 64 64
3 1024 1024 512 1024 512 1024 1024 1024 1024 1024
4 1024 1024 1024 1024 1024 1024 1024 1024 1024 1024
5 256 256 32 128 512 512 256 256 128 128
6 512 1024 1024 1024 512 512 512 512 1024 1024
7 512 1024 1024 1024 512 512 512 1024 1024 1024
8 256 1024 1024 1024 512 512 1024 1024 1024 1024
9 1024 1024 1024 1024 512 512 512 1024 1024 1024
10 1024 1024 512 1024 512 512 512 1024 1024 1024
11 512 256 1024 1024 512 512 1024 512 1024 1024
12 512 1024 1024 1024 512 512 1024 512 1024 1024
13 512 512 1024 1024 512 512 1024 1024 1024 1024
14 512 1024 1024 1024 512 512 1024 1024 1024 1024
15 512 1024 1024 1024 512 256 512 1024 1024 1024
16 1024 512 1024 1024 512 512 512 1024 1024 1024
17 1024 1024 1024 1024 512 512 512 1024 1024 1024
18 1024 1024 1024 1024 512 1024 1024 1024 1024 1024
19 1024 1024 1024 1024 512 1024 1024 1024 1024 1024
Ampicillin 2 >16 – – 0.5 >16 0.5 >16 – –
Cefuroxime 8 >16 – – 0.5 >16 – >16 – –
Ciprofloxacin <0.125 >16 0.25 >16 0.25 >16 1 >16 – –
İmipenem 0.25 0.25 1 >16 <0.125 >16 1 >16 – –
Meropenem <0.125 <0.125 1 8 <0.125 – 2 – – –
Fluconazole – – – – – – – – 1 64
Ampho-
thericin B – – – – – – – – 0.25 2
E.c. – Escherichia coli ATCC 25922; E.c.* – Escherichia coli isolate; P.a. – Pseudomonas aeruginosa ATCC 27853; P.a.* 
– Pseudomonas aeruginosa isolate; S.a. – Staphylococcus aureus ATCC 29213; S.a.* – Staphylococcus aureus isolate 
(MRSA); E.f. – Enterococcus faecalis ATCC 29212; E.f.* – Enterococcus faecium isolate (VRE); C.a. – Candida albi-
cans ATCC 10231. All isolates are resistant to ciprofloxacin.
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of susceptibility testing results. Beta-lactams should not be reported as susceptible for 
MRSA, even if tested as susceptible in vitro because beta-lactam breakpoints pose a 
risk for reporting MRSA isolates as falsely susceptible [7]. So, no higher concentra-
tions of ampicillin, cefuroxime and imipenem may be active against the studied 
MRSA strain. Through this knowledge and our results; all derivatives had lower 
antibacterial activity against the standard strain of S. aureus; however making a com-
parison for MRSA isolate, in this respect, is not possible.
The newly synthesized compounds exhibited antibacterial activities with MIC 
values between 128–1024 μg/mL against E. faecalis and E. faecium VRA isolate. 
According to the breakpoints of the agents for enterococci, the VRE isolate used in 
this study is also resistant to ampicillin, ciprofloxacin and imipenem [8]. The com-
pound 2 was found as the most potent derivative with a MIC value of 128 μg/mL 
against E. faecalis and E. faecium VRA isolate. 
All the newly synthesized benzoxazole derivatives exhibited antibacterial activity 
against the Gram-negative bacteria E. coli and P. aeruginosa and their respective 
drug-resistant isolates, with MIC values between 128 and 1024 µg/mL, except for 
derivative 5, which was the most effective compound against P. aeruginosa with a 
MIC value of 32 µg/mL. Thus, the compound having a phenyl group at position 2 of 
the benzoxazole ring and having a p-fluorophenylsulfonylamido group at position 5 
of the benzoxazole ring showed a stronger activity against P. aeruginosa than that 
having p-chloro and/or p-bromophenyl group at position 2 of benzoxazole ring. 
However, all the compounds possessed low antibacterial activity against tested Gram-
negative bacteria in comparison with standard drugs. The tested compounds (2–19) 
displayed antifungal activity against C. albicans and its isolate with MIC values 
between 128 and 1024 µg/mL. They displayed low antifungal activity in comparison 
with the antifungal reference drugs fluconazole and amphotericin B. 
In this study, we aimed to develop new effective antimicrobial agents possessing 
benzoxazole nuclei in their structure. Benzoxazole derivatives 2–19 as a new class of 
synthetic antimicrobial agents along with their in vitro antimicrobial activity tested 
against some Gram-negative, Gram-positive bacteria, and its isolate and C. albicans 
and its isolate. So that we put a para-substituted-phenyl sulfonylamido moiety on 
fifth position and different p-substituted phenyl groups on second position of benzo-
xazole ring for increasing the antimicrobial activity. Nevertheless, the benzoxazole 
derivatives were found to possess a broad spectrum of antimicrobial activity with 
MIC values of 32–1024 µg/mL and the standard drugs were more active against the 
tested pathogens. According to the results, the new compounds needed high concen-
trations to be active against the microorganisms. In this case, it is advisable to do 
further work in order to determine whether there is a synergistic effect of the new 
compounds with the reference antibiotics.
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